Advanced search

Vol 16, No 3 (2020)
Review paper
Published online: 2020-07-08

open access

View PDF Download PDF file
Page views 1921
Article views/downloads 2295
Get Citation

Connect on Social Media

Connect on Social Media

Diagnosis and treatment of angiomyolipoma (AML) tumours

Aleksandra Sobiborowicz12, Anna M. Czarnecka13, Anna Szumera-Ciećkiewicz45, Piotr Rutkowski1, Tomasz Świtaj1
DOI: 10.5603/OCP.2020.0008
Oncol Clin Pract 2020;16(3):116-132.

Abstract

Angiomyolipoma (AML) is the most commonly occurring tumour from the PEComa family (PEC tumours; perivascular
epithelioid cell tumours), a rare group of neoplasms of mesenchymal origin. AML may occur sporadically or
in the course of tuberous sclerosis and lymphangioleiomyomatosis. The sporadic type form is the most common
subtype of benign kidney tumours and is four times more frequent in women. Kid ney tumours of the angiomyolipoma
type are most commonly detected by chance during an abdominal cavity ultrasound scan, during which
they are visible as hyperechogenic tumours, and in most cases they are not a diagnostic problem. AML growth
is slow, and complications are rare. The main AML complication can be bleeding to the retroperitoneal space or
to the pelvicalyceal system. The typical method of AML care is active surveillance (AS). Asymptomatic tumours
with a diameter under 4 cm require control by ultrasound examination every 12 months whereas tumours with
a diameter of less than 2 cm are considered not to require control ultrasounds. AML with a diameter of over 4 cm
require more frequent ultrasound scans — every six months. The size of the tumour, the presence of symptoms
(e.g. pain in a tumour projection, haematuria), planned pregnancy, or suspicion of a malignant tumour are critical
in therapeutic decisions. Active treatment options include: embolisation, ablation techniques, nephron-sparing
surgery (NSS), and radical nephrectomy. In adult patients with tuberous sclerosis, who require treatment but do
not require rapid surgical treatment, everolimus is used. In the case of AML, initially doses of 1 × 10 mg per day
should be used (an appropriate dose decrease is required in the case of liver insufficiency), and subsequently
treatment may be individualised after determining the lowest effective dose with acceptable adverse effects. A rare
epithelioid variety of AML (EAML) shows the potential for a malignant course. The basis of EAML treatment is
radical resection, ensuring a high percentage of cures. For non-resectable EAML, chemotherapy, mTOR inhibitors,
and VEGFR inhibitors (pazopanib, apatinib) are used, but objective responses have been described only in
a very small percentage of patients

Keywords: AMLangiomyolipomaeverolimus

Article available in PDF format

View PDF Download PDF file

References

  1. Klimczak A, Pękul M, Wiater K, Rutkowski P. PEComa — grupa rzadkich nowotworów pochodzenia mezenchymalnego. NOWOTWORY Journal of Oncology. 2011; 61(1): 52–56.
  2. Fittschen A, Wendlik I, Oeztuerk S, et al. Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients. Abdom Imaging. 2014; 39(5): 1009–1013.
    CrossRefPubMed
  3. Słowińska M, Jóźwiak S, Peron A, et al. Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Orphanet J Rare Dis. 2018; 13(1): 25.
    CrossRefPubMed
  4. Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018; 178(3): 338–347.
    CrossRefPubMed
  5. Johnson SR, Cordier JF, Lazor R, et al. Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35(1): 14–26.
    CrossRefPubMed
  6. Aydin H, Magi-Galluzzi C, Lane BR, et al. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol. 2009; 33(2): 289–297.
    CrossRefPubMed
  7. Lee W, Choi SeY, Lee C, et al. Does epithelioid angiomyolipoma have poorer prognosis, compared with classic angiomyolipoma? Investig Clin Urol. 2018; 59(6): 357–362.
    CrossRefPubMed
  8. Casper KA, Donnelly LF, Chen B, et al. Tuberous sclerosis complex: renal imaging findings. Radiology. 2002; 225(2): 451–456.
    CrossRefPubMed
  9. Kingswood JC, Belousova E, Benedik MP, et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrol Dial Transplant. 2019; 34(3): 502–508.
    CrossRefPubMed
  10. Delhorme JB, Fontana A, Levy A, et al. Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions. Eur J Surg Oncol. 2017; 43(4): 831–836.
    CrossRefPubMed
  11. Seyam RM, Alkhudair WK, Kattan SA, et al. The risks of renal angiomyolipoma: reviewing the evidence. J Kidney Cancer VHL. 2017; 4(4): 13–25.
    CrossRefPubMed
  12. Brimo F, Robinson B, Guo C, et al. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol. 2010; 34(5): 715–722.
    CrossRefPubMed
  13. Faraji H, Nguyen BN, Mai KT. Renal epithelioid angiomyolipoma: a study of six cases and a meta-analytic study. Development of criteria for screening the entity with prognostic significance. Histopathology. 2009; 55(5): 525–534.
    CrossRefPubMed
  14. Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol. 2011; 35(2): 161–176.
    CrossRefPubMed
  15. Yang L, Feng XL, Shen S, et al. Clinicopathological analysis of 156 patients with angiomyolipoma originating from different organs. Oncol Lett. 2012; 3(3): 586–590.
    CrossRefPubMed
  16. He W, Cheville JC, Sadow PM, et al. Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors. Mod Pathol. 2013; 26(10): 1355–1364.
    CrossRefPubMed
  17. Lei JH, Liu LR, Wei Q, et al. A four-year follow-up study of renal epithelioid angiomyolipoma: a multi-center experience and literature review. Sci Rep. 2015; 5: 10030.
    CrossRefPubMed
  18. Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology. 2006; 68(4): 737–740.
    CrossRefPubMed
  19. Wang SF, Lo WO. Benign Neoplasm of Kidney: Angiomyolipoma. J Med Ultrasound. 2018; 26(3): 119–122.
    CrossRefPubMed
  20. Stachurski L, Pętlak O, Szyfer W. Obustronny naczyniakomięśniakotłuszczak nerki (angiomolipoma) leczony operacyjnie. Urologia Polska 1985; 38(4).
  21. Nelson C, Sanda M. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002: 1315–1325.
    CrossRef
  22. Prasad TV, Singh A, Das CJ, et al. An unusually large renal angiomyolipoma peeping into the right atrium. BMJ Case Rep. 2016; 2016.
    CrossRefPubMed
  23. Mettler J, Al-Katib S. Aggressive Renal Angiomyolipoma in a Patient With Tuberous Sclerosis Resulting in Pulmonary Tumor Embolus and Pulmonary Infarction. Urology. 2018; 119: e1–e2.
    CrossRefPubMed
  24. Nonomura A, Enomoto Y, Takeda M, et al. Angiomyolipoma of the liver: a reappraisal of morphological features and delineation of new characteristic histological features from the clinicopathological findings of 55 tumours in 47 patients. Histopathology. 2012; 61(5): 863–880.
    CrossRefPubMed
  25. Jóźwiak S, Sadowski K, Borkowska J, et al. Liver angiomyolipomas in tuberous sclerosis complex-their incidence and course. Pediatr Neurol. 2018; 78: 20–26.
    CrossRefPubMed
  26. Ozturk S, Unver M, Onen Z, et al. Giant extrarenal retroperitoneal angiomyolipoma: a rare case of a large size tumor. Clin Genitourin Cancer. 2018; 16(5): e1025–e1027.
    CrossRefPubMed
  27. Hulbert J, Graf R. Involvement of the spleen by renal angiomyolipoma: metastasis or multicentricity? J Urol. 1983; 130(2): 328–329.
    CrossRef
  28. Wang Y, Zhang X, Liu P, et al. Duodenal angiomyolipoma with multiple systemic vascular malformations and aneurysms: A case report and literature review. Oncol Lett. 2017; 14(6): 6659–6663.
    CrossRefPubMed
  29. Ail D, Paulose R, Kalitha A, et al. Gastric angiomyolipoma masquerading as gastric malignancy. ACG Case Reports Journal. 2018; 5(1): e96.
    CrossRef
  30. Peh SC, Sivanesaratnam V. Angiomyolipoma of the vagina--an uncommon tumour. Case report. Br J Obstet Gynaecol. 1988; 95(8): 820–823.
    CrossRefPubMed
  31. Chen KT. Angiomyolipoma of the vagina. Gynecol Oncol. 1990; 37(2): 302–304.
    CrossRefPubMed
  32. Garg M, Duhan A, Bindroo S, et al. Isolated angiomyolipoma of vulva: A case report of an uncommon tumor at an uncommon site. J Cancer Res Ther. 2015; 11(3): 645.
    CrossRefPubMed
  33. Anderson AE, Yang Xu, Young RH. Epithelioid angiomyolipoma of the ovary: a case report and literature review. Int J Gynecol Pathol. 2002; 21(1): 69–73.
    CrossRefPubMed
  34. Lee SJ, Yoo JY, Yoo SH, et al. Uterine angiomyolipoma with metastasis in a woman with tuberous sclerosis: a case report. Eur J Gynaecol Oncol. 2013; 34(4): 339–342.
    PubMed
  35. Castillenti T, Bertin A. Angiomyolipoma of the spermatic cord: case report and literature review. J Urol. 1989; 142(5): 1308–1309.
    CrossRef
  36. Sultan G, Masood B, Qureshi H, et al. Angiomyolipoma of the scrotum: report of a rarely seen case and review of the literature. Turk J Urol. 2017; 43(2): 223–226.
    CrossRefPubMed
  37. Piattelli A, Fioroni M, Rubini C, et al. Angiomyolipoma of the palate. Report of a case. Oral Oncol. 2001; 37(3): 323–325.
    CrossRefPubMed
  38. Banerjee SS, Eyden B, Trenholm PW, et al. Monotypic angiomyolipoma of the nasal cavity: a heretofore undescribed occurrence. Int J Surg Pathol. 2001; 9(4): 309–315.
    CrossRefPubMed
  39. Weindling SM, Menke DM, Bolger WE. Maxillary sinus angiomyolipoma: A case report and overview. Ear Nose Throat J. 2015; 94(7): E1–E4.
    CrossRefPubMed
  40. Cheah SC, Jaafar R, Jais MH. Huge buccal angiomyolipoma: a rare entity. Braz J Otorhinolaryngol. 2017 [Epub ahead of print].
    CrossRefPubMed
  41. Tchernev G, Philipov S, Ananiev J, et al. Angiomyolipoma of the helix without signs of systemic involvement: successful surgical approach. Int J Immunopathol Pharmacol. 2014; 27(4): 611–614.
    CrossRefPubMed
  42. Lu D, Yang H, Liu SXi, et al. A rare benign parotid gland tumor: angiomyolipoma. J Craniofac Surg. 2013; 24(6): e619–e621.
    CrossRefPubMed
  43. Hayashi K, Yamamoto M, Nishimura H, et al. Angiomyolipoma of the anterior mediastinum — a case report. Nihon Kyobu Geka Gakkai Zasshi. 1994; 42(4): 584–587.
    PubMed
  44. Knight CS, Cerfolio RJ, Winokur TS. Angiomyolipoma of the anterior mediastinum. Ann Diagn Pathol. 2008; 12(4): 293–295.
    CrossRefPubMed
  45. D'Antonio A, Caleo A, Caleo O, et al. Monotypic epithelioid angiomyolipoma of the adrenal gland: an unusual site for a rare extrarenal tumor. Ann Diagn Pathol. 2009; 13(5): 347–350.
    CrossRefPubMed
  46. Kim HJ, Chung CM, Park JY, et al. Angiomyolipoma of the Glabellar Region. Arch Craniofac Surg. 2017; 18(3): 202–206.
    CrossRefPubMed
  47. Insabato L, De Rosa G, Terracciano LM, et al. Primary monotypic epithelioid angiomyolipoma of bone. Histopathology. 2002; 40(3): 286–290.
    CrossRefPubMed
  48. Chen GX, Wang MH, Hu CL, et al. Angiomyolipoma of the rib: A rare case report. Mol Clin Oncol. 2016; 4(1): 126–128.
    CrossRefPubMed
  49. Garoufalia Z, Machairas N, Kostakis ID, et al. Malignant potential of epithelioid angiomyolipomas of the liver: A case report and comprehensive review of the literature. Mol Clin Oncol. 2018; 9(2): 226–230.
    CrossRefPubMed
  50. Lau SK, Marchevsky AM, McKenna RJ, et al. Malignant monotypic epithelioid angiomyolipoma of the retroperitoneum. Int J Surg Pathol. 2003; 11(3): 223–228.
    CrossRefPubMed
  51. Tuma J, Moch H, Stuckmann G, et al. Two in One: Epithelioid angiomyolipoma within a classic kidney angiomyolipoma — a case report. BMC Nephrol. 2018; 19(1): 123.
    CrossRefPubMed
  52. Książek A, Załuska W, Wysocki MW. Naczyniakomięśniakotłuszczak nerki. 2018.
  53. Park BK. Renal angiomyolipoma: radiologic classification and imaging features according to the amount of fat. AJR Am J Roentgenol. 2017; 209(4): 826–835.
    CrossRefPubMed
  54. Park SG, Park BK. New radiologic classification of renal angiomyolipoma: frequently asked questions. Clin Imaging. 2019; 55: 156–160.
    CrossRefPubMed
  55. Park BK. Renal Angiomyolipoma Based on New Classification: How to Differentiate It From Renal Cell Carcinoma. AJR Am J Roentgenol. 2019; 212(3): 582–588.
    CrossRefPubMed
  56. Bauman TM, Potretzke AM, Wright AJ, et al. Patient and nonradiographic tumor characteristics predicting lipid-poor angiomyolipoma in small renal masses: Introducing the BEARS index. Investig Clin Urol. 2017; 58(4): 235–240.
    CrossRefPubMed
  57. Williams CH, Hickle K, Bakke K, et al. Hepatic epithelioid angiomyolipoma treated with laparoscopic resection: case report and review of the literature. Case Reports Hepatol. 2019: 2362618.
    CrossRefPubMed
  58. Liu W, Wang J, Huang Q, et al. Comparison of MRI features of epithelioid hepatic angiomyolipoma and hepatocellular carcinoma: imaging data from two centers. Front Oncol. 2018; 8: 600.
    CrossRefPubMed
  59. Soma T, Ishioka J, Tanaka H, et al. Potential for computer-aided diagnosis using a convolutional neural network algorithm to diagnose fat-poor angiomyolipoma in enhanced computed tomography and T2-weighted magnetic resonance imaging. Int J Urol. 2018; 25(11): 978–979.
    CrossRefPubMed
  60. Cui EM, Lin F, Li Q, et al. Differentiation of renal angiomyolipoma without visible fat from renal cell carcinoma by machine learning based on whole-tumor computed tomography texture features. Acta Radiol. 2019; 60(11): 1543–1552.
    CrossRefPubMed
  61. Malewski W. Diagnostyka i leczenie nerkowych naczyniakomięśniakotłuszczaków nerki. Przegląd Urologiczny 2016; 5(99).
  62. Chen LS, Zhu ZQ, Wang ZT, et al. Chemical shift magnetic resonance imaging for distinguishing minimal-fat renal angiomyolipoma from renal cell carcinoma: a meta-analysis. Eur Radiol. 2018; 28(5): 1854–1861.
    CrossRefPubMed
  63. Dębska-Ślizień A, Tarasewicz A, Król E, et al. Zasady postępowania z chorym z nerkową manifestacją stwardnienia guzowatego. Stanowisko Grupy Roboczej Stwardnienia Guzowatego Polskiego Towarzystwa Nefrologicznego. Nefrologia i Dializoterapia Polska. 2016; 20: 134–147.
  64. Domańska-Pakieła D, Kotulska K, Jóźwiak S. Stwardnienie guzowate: postępy w diagnostyce i leczeniu. Neurologia Dziecięca. 2008; 17(33): 11–22.
  65. Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. Ann Diagn Pathol. 2015; 19(5): 359–368.
    CrossRefPubMed
  66. Jinzaki M, Silverman SG, Akita H, et al. Diagnosis of renal angiomyolipomas: classic, fat-poor, and epithelioid types. Semin Ultrasound CT MR. 2017; 38(1): 37–46.
    CrossRefPubMed
  67. Tsai HY, Lee KH, Ng KF, et al. Clinicopathologic analysis of renal epithelioid angiomyolipoma: Consecutively excised 23 cases. Kaohsiung J Med Sci. 2019; 35(1): 33–38.
    CrossRefPubMed
  68. LeRoy MA, Rao P. Angiomyolipoma with epithelial cysts. Arch Pathol Lab Med. 2016; 140(6): 594–597.
    CrossRefPubMed
  69. Wood A, Young F, O'Donnell M. Angiomyolipoma with epithelial cysts masquerading as a cystic renal cell carcinoma. Curr Urol. 2017; 9(4): 209–211.
    CrossRefPubMed
  70. Nell RJ, Wong DD, van Vliet C, et al. Inflammatory angiomyolipoma of the liver: a diagnostic pitfall. Pathology. 2018; 50(3): 352–355.
    CrossRefPubMed
  71. Guan H, Zhang L, Zhang Q, et al. Primary angiosarcoma arising in an angiomyolipoma of the kidney: case report and literature review. Diagn Pathol. 2018; 13(1): 53.
    CrossRefPubMed
  72. Wang CN, Wang SY, Lin MJ, et al. Occult renal cell carcinoma of eosinophilic morphology detected within renal angiomyolipoma mass in a patient with tuberous sclerosis complex. Chin Med J (Engl). 2017; 130(12): 1505–1506.
    CrossRefPubMed
  73. Roma AA, Magi-Galluzzi C, Zhou M. Differential expression of melanocytic markers in myoid, lipomatous, and vascular components of renal angiomyolipomas. Arch Pathol Lab Med. 2007; 131(1): 122–125.
    CrossRefPubMed
  74. Makhlouf HR, Remotti HE, Ishak KG. Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol. 2002; 26(4): 493–497.
    CrossRefPubMed
  75. Caliò A, Brunelli M, Segala D, et al. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma. Mod Pathol. 2018; 31(3): 474–487.
    CrossRefPubMed
  76. Bi XG, Guo L, Wang XL, et al. Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study. Oncol Lett. 2017; 14(1): 695–704.
    CrossRefPubMed
  77. Park JH, Lee C, Suh JaH, et al. Renal epithelioid angiomyolipoma: Histopathologic review, immunohistochemical evaluation and prognostic significance. Pathol Int. 2016; 66(10): 571–577.
    CrossRefPubMed
  78. Mete O, van der Kwast TH. Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms. Arch Pathol Lab Med. 2011; 135(5): 665–670.
  79. Komarowska H, Bednarek-Rajewska K, Kański M, et al. Epithelioid angiomyolipoma mimicking adrenal cortical carcinoma: A diagnostic pitfall. Oncol Lett. 2015; 10(4): 2130–2134.
    CrossRefPubMed
  80. Yan Z, Grenert JP, Joseph NM, et al. Hepatic angiomyolipoma: mutation analysis and immunohistochemical pitfalls in diagnosis. Histopathology. 2018; 73(1): 101–108.
    CrossRefPubMed
  81. Randle SC. Tuberous sclerosis complex: a review. Pediatr Ann. 2017; 46(4): e166–e171.
    CrossRefPubMed
  82. Krymskaya VP. Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal. 2003; 15(8): 729–739.
    CrossRefPubMed
  83. Li S, Zhang Y, Wang Z, et al. Genotype-phenotype correlation of patients with tuberous sclerosis complex-associated renal angiomyolipoma: a descriptive study. Hum Pathol. 2018; 82: 61–67.
    CrossRefPubMed
  84. Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 2007; 38(9): 1361–1371.
    CrossRefPubMed
  85. Pleniceanu O, Omer D, Azaria E, et al. mTORC1 inhibition is an effective treatment for sporadic renal angiomyolipoma. Kidney Int Rep. 2018; 3(1): 155–159.
    CrossRefPubMed
  86. Cho JH, Patel B, Bonala S, et al. The Codon 72 Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis. Mol Cancer Res. 2019; 17(8): 1639–1651.
    CrossRefPubMed
  87. Thibodeau MyL, Steinraths M, Brown L, et al. Genomic and cytogenetic characterization of a balanced translocation disrupting NUP98. Cytogenet Genome Res. 2017; 152(3): 117–121.
    CrossRefPubMed
  88. Małuszek M. Multifunctionality of MDM2 protein and its role in genomic instability of cancer cells. Postepy Biochem. 2015; 61(1): 42–51.
    PubMed
  89. Inoue C, Saito R, Nakanishi W, et al. Renal epithelioid angiomyolipoma undergoing aggressive clinical outcome: the MDM2 expression in tumor cells of two cases. Tohoku J Exp Med. 2019; 247(2): 119–127.
    CrossRefPubMed
  90. Kidawa A, Kurpiński A, Idzikowski K. Obustronny naczyniakomięśniakotłuszczak angiomyolipoma) nerek. Urologia Polska. 1992; 45(3).
  91. Ruud Bosch JLH, Vekeman F, Duh MS, et al. Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center. Int Urol Nephrol. 2018; 50(3): 459–467.
    CrossRefPubMed
  92. Fernández-Pello S, Hora M, Kuusk T, et al. Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. Eur Urol Oncol. 2019 [Epub ahead of print].
    CrossRefPubMed
  93. Wang C, Li X, Peng L, et al. An update on recent developments in rupture of renal angiomyolipoma. Medicine (Baltimore). 2018; 97(16): e0497.
    CrossRefPubMed
  94. Arslan B, Gürkan O, Çetin B, et al. Evaluation of ABO blood groups and blood-based biomarkers as a predictor of growth kinetics of renal angiomyolipoma. Int Urol Nephrol. 2018; 50(12): 2131–2137.
    CrossRefPubMed
  95. Janssens P, Van Hoeve K, De Waele L, et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr Nephrol. 2018; 33(11): 2085–2093.
    CrossRefPubMed
  96. Rentz AM, Skalicky AM, Liu Z, et al. Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. J Patient Rep Outcomes. 2018; 2: 30.
    CrossRefPubMed
  97. Ljungberg B, Albiges L, Bensalah K, et al. European Association of Urology Guidelines on Renal Cell Carcinoma 2017. 2017.
  98. Chan KE, Chedgy E, Bent CL, et al. Surveillance imaging for sporadic renal angiomyolipoma less than 40 mm: lessons learnt and recommendations from the experience of a large district general hospital. Ann R Coll Surg Engl . 2018; 100(6): 480–484.
    CrossRef
  99. Ouzaid I, Autorino R, Fatica R, et al. Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. BJU Int. 2014; 114(3): 412–417.
    CrossRefPubMed
  100. Vos N, Oyen R. Renal angiomyolipoma: the good, the bad, and the ugly. J Belg Soc Radiol. 2018; 102(1): 41.
    CrossRefPubMed
  101. Kuusk T, Biancari F, Lane B, et al. Treatment of renal angiomyolipoma: pooled analysis of individual patient data. BMC Urol. 2015; 15: 123.
    CrossRefPubMed
  102. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One. 2017; 12(8): e0180939.
    CrossRefPubMed
  103. Buj Pradilla MJ, Martí Ballesté T, Torra R, et al. Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex. Clin Kidney J. 2017; 10(6): 728–737.
    CrossRefPubMed
  104. Ryan JW, Farrelly C, Geoghegan T. What are the indications for prophylactic embolization of renal angiomyolipomas? A review of the current evidence in the literature. Can Assoc Radiol J. 2018; 69(3): 236–239.
    CrossRefPubMed
  105. Peng Zf, Yang Lu, Wang Tt, et al. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review. J Urol. 2014; 192(5): 1424–1430.
    CrossRefPubMed
  106. Canpolat M, Gumus H, Kumandas S, et al. The use of rapamycin in patients with tuberous sclerosis complex: Long-term results. Epilepsy Behav. 2018; 88: 357–364.
    CrossRefPubMed
  107. Kingswood JC, Jozwiak S, Belousova ED, et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrol Dial Transplant. 2014; 29(6): 1203–1210.
    CrossRefPubMed
  108. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869): 817–824.
    CrossRefPubMed
  109. Bissler JJ, Budde K, Sauter M, et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transplant. 2019; 34(6): 1000–1008.
    CrossRefPubMed
  110. Bissler JJ, Nonomura N, Budde K, et al. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS One. 2018; 13(9): e0201005.
    CrossRefPubMed
  111. Bissler JJ, Franz DN, Frost MD, et al. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatr Nephrol. 2018; 33(1): 101–109.
    CrossRefPubMed
  112. Cai Yi, Guo H, Wang W, et al. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J Rare Dis. 2018; 13(1): 43.
    CrossRefPubMed
  113. Zonnenberg BA, Neary MP, Duh MS, et al. Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus. PLoS One. 2018; 13(11): e0204646.
    CrossRefPubMed
  114. Hatano T, Inaba H, Endo K, et al. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex. Int J Urol. 2017; 24(11): 780–785.
    CrossRefPubMed
  115. Wei CC, Tsai JD, Sheu JN, et al. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study. J Investig Med. 2019; 67(3): 686–690.
    CrossRefPubMed
  116. Toriu N, Mizuno H, Sawa N, et al. Everolimus reduces the size of tuberous sclerosis complex-related huge renal angiomyolipomas exceeding 20 cm in the longest diameter. Case Rep Oncol. 2018; 11(2): 258–267.
    CrossRefPubMed
  117. Hatano T, Matsu-Ura T, Mori KI, et al. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization. Int J Clin Oncol. 2018; 23(6): 1134–1139.
    CrossRefPubMed
  118. Hatano T, Atsuta M, Inaba H, et al. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density. Int J Clin Oncol. 2018; 23(3): 547–552.
    CrossRefPubMed
  119. Brakemeier S, Vogt L, Adams L, et al. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC). PLoS One. 2017; 12(12): e0189132.
    CrossRefPubMed
  120. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358(2): 140–151.
    CrossRefPubMed
  121. Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One. 2011; 6(9): e23379.
    CrossRefPubMed
  122. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011; 17(12): 4071–4081.
    CrossRefPubMed
  123. Cabrera-López C, Martí T, Catalá V, et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J Rare Dis. 2012; 7: 87.
    CrossRefPubMed
  124. De Bree E, Stamatiou D, Chryssou E, et al. Late local, peritoneal and systemic recurrence of renal angiomyolipoma: A case report. Mol Clin Oncol. 2019; 10(1): 43–48.
    CrossRefPubMed
  125. Klompenhouwer AJ, Verver D, Janki S, et al. Management of hepatic angiomyolipoma: A systematic review. Liver Int. 2017; 37(9): 1272–1280.
    CrossRefPubMed
  126. Zhan R, Li YQ, Chen CY, et al. Primary kidney malignant epithelioid angiomyolipoma: Two cases report and review of literature. Medicine (Baltimore). 2018; 97(32): e11805.
    CrossRefPubMed
  127. Damaskos C, garmpis N, garmpi A, et al. Angiomyolipoma of the liver: a rare benign tumor treated with a laparoscopic approach for the first time. In vivo. 2017; 31(6): 1169–1173.
  128. Seker M, Aksoy S, Babacan NA, et al. Renal epithelioid angiomyolipoma: successfully treated with chemotherapy. Acta Medica. 2013; 2: 35–37.
  129. Espinosa M, Roldán-Romero JM, Duran I, et al. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. BMC Cancer. 2018; 18(1): 561.
    CrossRefPubMed
  130. Higa F, Uchihara T, Haranaga S, et al. Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus. Internal Medicine. 2009; 48(20): 1821–1825.
    CrossRef
  131. Wolff N, Kabbani W, Bradley T, et al. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol. 2010; 28(5): e65–e68.
    CrossRefPubMed
  132. Shitara K, Yatabe Y, Mizota A, et al. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. Jpn J Clin Oncol. 2011; 41(6): 814–816.
    CrossRefPubMed
  133. Kohno J, Matsui Y, Yamasaki T, et al. Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: a case report. Int J Urol. 2013; 20(9): 938–941.
    CrossRefPubMed
  134. Faria E, Turturro F, Rao P, et al. Malignant epithelioid angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography. Clin Genitourin Cancer. 2013; 11(4): e1–e5.
    CrossRefPubMed
  135. Wyluda E, Baquero G, Lamparella N, et al. Fatal malignant metastastic epithelioid angiomyolipoma presenting in a young woman: case report and review of the literature. Rare Tumors. 2013; 5(3): e46.
    CrossRefPubMed
  136. Hong J, Lee J, Kim K-M, Joo Kim S. Tumor response to temsirolimus for epithelioid angiomyolipoma and novel mutation of SMARCB1/INI1 tumor suppressor gene. Journal of Cancer Therapy. 2014; 05: 1215–1222.
  137. Binyamin K, Mecz Y, Stein A, et al. An aggressive case of malignant renal pecoma non-responsive to motor inhibition: a case report. Journal of Clinical Case Reports. 2016; 6(10): 1–3.
    CrossRef
  138. Anwar H, Sachpekidis C, Schwarzbach M, Dimitrakopoulou-Strauss A. Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: Response to mammalian target of rapamycin inhibitor therapy. Hell J Nucl Med. 2017; 20(2): 169–171.
  139. Huľová S, Sycova-Mila Z, Macák D, et al. Diagnostic challenges and extraordinary treatment response in rare malignant PEComa tumor of the kidney. Klin Onkol. 2018; 31(6): 448–452.
    CrossRefPubMed
  140. Lattanzi M, Deng FM, Chiriboga LA, et al. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. J Immunother Cancer. 2018; 6(1): 97.
    CrossRefPubMed
  141. Tayal J, Doval D, Kamboj M, et al. Case report of everolimus-induced sustained partial response in metastatic renal epithelioid angiomyolipoma. Türk Üroloji Dergisi/Turkish Journal of Urology. 2019; 45(-1): 139–142.
    CrossRef
  142. Ge X, Xue X, Zhang Ge, et al. Successful treatment of liver and abdomen metastasis of renal epithelioid angiomyolipoma with apatinib: a case report. Translational Cancer Research. 2017; 6(5): 1015–1019.
    CrossRef

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Oncology in Clinical Practice

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice